Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | GFER | P55789 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | CASP3 | P42574 | 2/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29819658 | 1.00 | NPC1 (0.65) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL29819557 | 1.00 | NPC1 (0.65) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL3288218 | 0.97 | NPC1 (0.66) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL14947174 | 0.92 | NPC1 (0.75) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL24295191 | 0.91 | SMN1; SMN2 (0.65) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL15745637 | 0.90 | NPC1 (0.73) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL3288472 | 0.90 | NPC1 (0.78) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL8345323 | 0.89 | NPC1 (0.57) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL11134813 | 0.89 | NPC1 (0.57) | NPC1RAB9AGFERSMN1; SMN2KDM4E | |
| SCHEMBL29881441 | 0.89 | NPC1 (0.57) | NPC1RAB9AGFERSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| CN-114957152-B | Synthesis method of benzoxazole compound | 湖南第一师范学院 | 2023-11-17 | — | — | CN | disclosed |
| CN-114957152-A | Synthetic method of benzoxazole compound | 湖南第一师范学院 | 2022-08-30 | — | — | CN | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-9856208-B2 | Method for producing an arene with an aromatic C—N bond ortho to an aromatic C—O bond | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-01-02 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20170066711-A1 | METHOD FOR PRODUCING AN ARENE WITH AN AROMATIC C-N BOND ORTHO TO AN AROMATIC C-O BOND | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-03-09 | — | — | US | disclosed |
| US-20170066711-A1 | METHOD FOR PRODUCING AN ARENE WITH AN AROMATIC C-N BOND ORTHO TO AN AROMATIC C-O BOND | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-03-09 | — | — | US | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| EP-1032850-B1 | SELF-SCINTILLATING SHEET MATERIAL FOR RADIOACTIVE SPECIES ANALYSIS | MINNESOTA MINING & MFG (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1183554-A1 | IN-SITU RADIOACTIVITY DETECTION | 3M Innovative Properties Company (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000077545-A1 | IN-SITU RADIOACTIVITY DETECTION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6139749-A | CONTACTING ENVIRONMENTAL FLUID WITH COMPOSITE SHEET MATERIAL COMPRISING SEPARATORS AND SCINTILLATORS ENTRAPPED IN POROUS MATRIX OR MEMBRANE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NPC1 28/4885RAB9A 2557/4885GFER 1034/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885GFER 4513/4885 |
| US-20170066711-A1 | METHOD FOR PRODUCING AN ARENE WITH AN AROMATIC C-N BOND ORTHO TO AN AROMATIC C-O BOND | AOX1, NOX4, NOXO1 | NPC1 1680/4885RAB9A 769/4885GFER 1057/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | NPC1 29/4885RAB9A 2302/4885GFER 1096/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | NPC1 28/4885RAB9A 2557/4885GFER 1034/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NPC1 28/4885RAB9A 2557/4885GFER 1034/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | NPC1 38/4885RAB9A 1885/4885GFER 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.